Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Fig. 3

IPWRA Analysis for the EORTC QLQ-C30 and EORTC QLQ-BR23a GHS/QoL, Functional Scales, and Symptom Scales. Mean GHS/QoL and functional scales (A) and symptoms scale (B) scores adjusted for patient demographic and clinical variables by IPWRA for patients treated with PARPi and chemotherapy. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Core 30; EORTC QLQ-BR23, European Organisation for Research and Treatment of Cancer Quality of Life Breast Cancer module; GHS/QoL, global health status/quality of life; IPWRA, inverse-probability–weighted regression adjustment; PARPi, poly (ADP-ribose) polymerase inhibitors. EORTC QLQ-BR23 category Sexual Enjoyment was excluded owing to low sample size. *Includes platinum- and non–platinum-based regimens. Bold P values represent those that are statistically significant (p < 0.05). Error bars represent standard error

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us